Arvinas, Inc. (ARVN) is a breakthrough biopharmaceutical company pioneering the development of targeted therapies for serious diseases. Its unique approach revolutionizes traditional methods of cancer treatment by focusing on protein degradation. This method has the potential to provide treatments for diseases that have been resistant to various therapies.
Arvinas was founded by Craig Crews, a professor at Yale University, in 2013 and is headquartered in New Haven, Connecticut, United States. The company derives its name from the Latin phrase "arvina", which translates to "the grease of sheep's wool". This represents a dedication to creating transformative solutions in the medical field, much as the grease of sheep's wool was used historically in myriad unique applications.
Highlighted by its Proteolysis-Targeting Chimeras (PROTAC) technology, Arvinas stands out in the pharmaceutical world. PROTAC harnesses the body's own natural process of protein degradation to eliminate disease-causing proteins, enabling innovations in treatment across a multitude of serious diseases, including cancer and neurodegenerative disorders.
Arvinas' lead products, ARV-110 and ARV-471, are proprietary investigational medications administered orally which are being evaluated for safety, tolerability, and durability of anti-tumor responses to potential treatments in phases of clinical trials. ARV-110 is an androgen receptor PROTAC protein degrader, being studied in men with metastatic castrate-resistant prostate cancer. ARV-471 is an estrogen receptor PROTAC protein degrader, undergoing clinical trials for patients with locally advanced or metastatic ER+/HER2- breast cancer.
Arvinas has also been actively contributing to research in neurodegenerative diseases. As of now, it's working extensively on a potential treatment for Huntington's disease and is also engaged in the development of a new class of small molecule drugs known as protein homeostasis regulators to treat serious neurological conditions, such as amyotropic lateral sclerosis (ALS) and frontal temporal dementia (FTD).
The company’s work has attracted the attention of large pharmaceuticals. Its high-profile partnerships include collaborations with Pfizer and Genentech, boosting its financial stability and R&D capabilities.
Arvinas, Inc.'s main distinction lies in its dedication to revolutionizing the approach to serious illnesses by introducing revolutionary methods based on protein degradation.
Stock exchange-wise, ARVN is traded publicly on Nasdaq and has had a strong growth trajectory. While any biotech venture carries inherit risk, Arvinas, Inc. demonstrates a promising future with its powerful technology platform and strategic partnerships. Overall, the company portrays a solid commitment towards treating deadly diseases with its innovative science and strategic collaborations. As the company continues its research and moves closer to FDA approval for its therapies, it will certainly be one to watch.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

Zacks Research has downgraded Arvinas (NASDAQ:ARVN) from a "strong buy" to a "hold" rating, though the overall analyst consensus remains "Moderate Buy" with a target price of $15.18. The company's recent quarterly earnings reported a beat on EPS at -$0.82 but significantly missed revenue expectations at $0.50 million, a 98.8% year-over-year decrease. Despite the downgrade, shares were up 2.4% on the day, opening at $6.92.

Arvinas, Inc. (Nasdaq: ARVN) announced its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company is a clinical-stage biotechnology firm focused on targeted protein degradation to develop new drugs. A live audio webcast of the presentation will be available for interested parties.

Arvinas reported its Q3 2026 financial results, showcasing $558.9 million in cash and equivalents and a projected cash runway into the second half of 2028. The company is advancing several clinical trials, including ARV393 for lymphoma and ARV027 for spinal bulbar muscular atrophy, with key data readouts anticipated in 2027. Management emphasized data-driven capital allocation and plans to initiate a Phase 1b trial for ARV102 in Europe and the UK for neurodegenerative diseases.

Arvinas, Inc. has filed a Form S-3 shelf registration statement with the SEC, allowing for a potential securities offering of up to $400 million. This total includes a specific $200 million at-the-market (ATM) common stock facility. Piper Sandler & Co. and Cantor Fitzgerald & Co. are named as agents for the ATM sales, with the registration pending effectiveness at the time of filing.
Arvinas, Inc. reported its third-quarter 2026 financial results, highlighting significant progress in its clinical-stage protein degrader programs, including the initiation of dosing for ARV-6723 and upcoming clinical data presentations for ARV-393, ARV-027, and ARV-6723. The company reaffirmed its financial guidance, indicating sufficient cash to fund operations into the second half of 2028, despite a decrease in R&D and G&A expenses compared to the previous year.
Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company specializing in targeted protein degradation, announced it will report its third-quarter 2026 financial results and provide a corporate update on Tuesday, November 3, 2026, at 8:00 a.m. ET via a live webcast. The company is advancing multiple investigational drugs through clinical development, targeting various diseases including non-Hodgkin Lymphoma, neurodegenerative disorders, spinal-bulbar muscular atrophy, and solid tumors.
Arvinas, Inc. has announced the return of its Early Career Researcher Award, offering a $25,000 monetary prize to recognize emerging talent in targeted protein degradation (TPD). Nominations will open on November 1, 2026, and close on December 31, 2026, with the winner to be announced in mid-2027. The award aims to foster innovation and creative thinking in the field of TPD, supporting the next generation of scientists.

Arvinas, Inc. (ARVN) recently achieved its best quarter due to a one-time Vepinu windfall, but its stock has fallen since, raising concerns about its narrowed clinical pipeline and decreasing cash reserves. With a third-quarter report approaching, the company faces scrutiny over its ability to deliver on remaining pipeline commitments like ARV393 and ARV027, as well as addressing setbacks for ARV806 and ARV102. Investors are looking for strong execution and clear timelines to maintain confidence in Arvinas's long-term strategy rather than viewing the Vepinu approval as a peak achievement.